Acquired factor FXIII (FXIII) deficiency can be immune- or non-immune mediated and may cause severe bleeding symptoms. The incidence of acquired FXIII...

Multiple myeloma (MM) is a heterogeneous neoplasm accounting for the second most prevalent hematologic disorder.

The pathogenesis of venous thromboembolism in multiple myeloma is still poorly understood because multiple factors are involved. In particular, the...

Randomised controlled trials comparing the effect of exercise interventions with usual care in adults with a diagnosis of multiple myeloma.

Recent advances in the genomic and molecular characterization of PTCL, with enhanced understanding of pathobiology, have translated into significant...

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the...

Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities...

Therefore, clinical management is often based on this limited literature and extrapolation of data from the more common, nodal T-cell lymphomas in...

Non-chromosomal birth defects are an important risk factor for several childhood cancers. However, these associations are less clear for Hodgkin...

The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others...

Multiple myeloma (MM) is a hematological malignancy that develops over years from the asymptomatic precursors, monoclonal gammopathy of undetermined...

The extranodal mature T-cell and NK-cell lymphomas and lymphoproliferative disorders represent a unique group of rare neoplasms with both overlapping...